DCIS
Conditions
Keywords
Ductal Carcinoma in Situ, Breast Conserving Surgery, Oncotype DX DS
Brief summary
To evaluate whether the combination of clinicopathological factors and the use of the Oncotype DX DCIS score can avoid radiation in women with low risk DCIS who have had breast conserving surgery (BCS)
Detailed description
A prospective cohort study, conducted in Canada, to prospectively evaluate whether the combination of clinicopathological criteria and the Oncotype DX DCIS score can identify a group of women at very low risk of local recurrence following breast conserving surgery who do not require breast radiation therapy. We plan to screen 809 consenting women who will have their tumour tissue specimen sent to Exact Sciences to assess their DCIS score. We anticipate that 526 women will have an Oncotype DX DCIS score with a predicted 10-year risk of local recurrence ≤10%, these women will be enrolled and followed as part of the study. At each centre, all patients with DCIS referred to radiation oncology will be documented. When a physician identifies an eligible patient, the patient will be approached by the referring physician or delegate to voluntarily provide informed consent to participate in this study. Consenting patients will be registered through the Ontario Clinical Oncology Group's (OCOG) web-based registration system. A two-step registration/enrollment process will be implemented. Data related to the patient demographics, surgery details, tumour characteristics and ECOG performance will be collected. The patient's tumour specimen will be sent for analysis to Exact Sciences. The DCIS score results will be sent to the referring physician. OCOG will also receive the DCIS score results. Patients will be followed yearly up to 10 years. Bilateral mammograms and breast exams will be performed annually. The study data will be verified by source documentation.
Interventions
None listed
Sponsors
Ontario Clinical Oncology Group (OCOG)
Canadian Institutes of Health Research (CIHR)
Hamilton Health Sciences Corporation
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
46 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Female patient \> 45 years of age with DCIS without microinvasion. 2. Tumour size ≤ 2.5cm. 3. Treated by BCS with clear resection margins ≥ 2 mm or no residual disease on re-excision.\* \* Patients with anterior margins and posterior margins ≥1 mm are eligible. Or if the dissection was confirmed to be taken to skin and down to fascia with no DCIS present at inked margins. 4. Oncotype DX DCIS score with a predicted 10-year risk of LR ≤10%.
Exclusion criteria
1. Multifocal DCIS. 2. History of any invasive breast cancer or non-invasive breast cancer in the ipsilateral breast. 3. Synchronous or previous invasive or non-invasive breast cancer. 4. Prior history of invasive cancer within the last 5 years, excluding non-melanoma skin cancers. 5. ECOG performance status ≥3. 6. Life expectancy \<10 years. 7. Geographic inaccessibility for follow-up.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Ipsilateral local recurrence (LR) | 5 Year | Defined as recurrent invasive or in situ cancer in the ipsilateral breast |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Ipsilateral invasive local recurrence | 5 Year | defined as time from study registration to time of recurrent invasive cancer in the ipsilateral breast |
| Breast cancer recurrence-free interval (RFI) | 5 Year | defined as time from study registration to time of documented recurrent disease (ipsilateral breast (DCIS or invasive), regional, distant or death from breast cancer |
| Distant disease-free survival (DDFS) | 5 Year | defined as time from study registration to distant recurrence |
| Disease-free survival (DFS) | 5 Year | defined as time from registration to time of LR (DCIS or invasive), regional and distant recurrence, contralateral breast cancer, new primary (non-breast) and death from any cause |
| Overall survival (OS) | 5 Year | defined as time from registration to death of any cause |
Countries
Canada
Contacts
CONTACTBrittany Speller
PRINCIPAL_INVESTIGATOREileen Rakovitch, M.D.
Sunnybrook Research Institute, Sunnybrook Health Science
PRINCIPAL_INVESTIGATORTim Whelan, M.D
Juravinski Cancer Centre
Outcome results
None listed